Bone Sarcoma Clinical Trial
Official title:
Real-Time Contrast Enhanced Ultrasound and Ultrasound-Based Elastography: Novel Quantitative Imaging Techniques for Early Therapy Response Assessment in Sarcomas
This pilot clinical trial studies real-time contrast-enhanced ultrasonography and shear wave elastography in predicting treatment response in patients with soft tissue sarcomas. Ultrasonography and elastography are diagnostic imaging tests that use sound waves to make pictures of the body without using radiation (x-rays). Real-time contrast-enhanced ultrasonography and shear wave elastography may help measure a patient's response to treatment given before surgery in patients with soft tissue sarcoma.
PRIMARY OBJECTIVES: I. To investigate whether two different radiologists can reliably interpret the following quantitative criteria regarding the maximally enhancing portion of a soft tissue sarcoma (STS), on sequential contrast-enhanced ultrasound (CEUS) exams performed before, during, and after neoadjuvant chemotherapy (NAC): change in peak enhancement (decibels), change in slope of enhancement curve, and change in area under the curve. II. To evaluate CEUS as a potential early response assessment biomarker by comparing the CEUS rating result to computed tomography (CT)/magnetic resonance imaging (MRI) rating results. (Exploratory) III. To examine the agreement between CEUS versus CT/MRI determined treatment response within each radiologist rater. (Exploratory) IV. To examine the agreement between CEUS versus CT/MRI determined treatment response based on the consensus rating result from the two radiologist raters. (Exploratory) V. To explore potential quantitative biomarker from all possible parameters that can be extracted from CEUS data for assessing an early treatment response to neoadjuvant therapy (NAT) in sarcoma using receiver operating characteristic (ROC) curve when predicting radiologists rated binary outcome: responders versus non-responders. (Exploratory) VI. To collect preliminary data for shear wave elastography (SWE) in the same patient population. (Exploratory) OUTLINE: Patients undergo real-time CEUS and SWE at baseline, 6 weeks after initiation of neoadjuvant therapy, and 9 weeks after initiation of neoadjuvant therapy (prior to surgery). After completion of study, patients are followed up at 24 hours. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05621668 -
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
|
Phase 1 | |
| Not yet recruiting |
NCT05515068 -
Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas
|
||
| Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
| Active, not recruiting |
NCT00592293 -
Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
|
N/A | |
| Recruiting |
NCT05051059 -
Assessment of the Functional Outcome and Quality of Life in Sarcoma Patients
|
N/A | |
| Recruiting |
NCT06129903 -
Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma
|
N/A | |
| Completed |
NCT06202599 -
Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance
|
||
| Recruiting |
NCT04634227 -
Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)
|
Early Phase 1 | |
| Recruiting |
NCT03277924 -
Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03462316 -
NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma
|
Phase 1 | |
| Recruiting |
NCT04055220 -
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
|
N/A | |
| Completed |
NCT02520128 -
A Study of IMRT in Primary Bone and Soft Tissue Sarcoma
|
N/A | |
| Completed |
NCT02301039 -
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
|
Phase 2 | |
| Withdrawn |
NCT05116800 -
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
|
Phase 2 | |
| Recruiting |
NCT04181970 -
Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK
|
||
| Completed |
NCT00525057 -
Dalteparin in Preventing DVT in Participants With Cancer
|
N/A | |
| Recruiting |
NCT04698785 -
Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
|
Phase 2 | |
| Completed |
NCT01588522 -
Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease
|
Phase 1 | |
| Terminated |
NCT03468075 -
Gemcitabine Plus Ascorbate for Sarcoma in Adults
|
Phase 2 | |
| Recruiting |
NCT04616248 -
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
|
Phase 1 |